FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2143342566> ?p ?o ?g. }

• W2143342566 endingPage "2096" @default.
• W2143342566 startingPage "2090" @default.
• W2143342566 abstract "BACKGROUND. Outcome of patients with relapsed acute myeloid leukemia (AML) remains unsatisfactory. Clofarabine is a nucleoside analog with activity in adult AML. Combinations with cytarabine in AML are feasible and effective. Idarubicin is another active AML drug, which has not yet been tested with clofarabine. METHODS. The authors therefore designed a phase I study of clofarabine ± cytarabine, plus idarubicin. Patients with primary refractory or first-relapse AML were assigned to either clofarabine plus idarubicin (CI) if previously exposed to cytarabine with a response lasting <12 months, or clofarabine and idarubicin plus cytarabine (CIA) for responses ≥12 months, or if never exposed to cytarabine. A standard “3 + 3” phase 1 design was followed to define maximum tolerated dose (MTD). Forty-four patients were treated (23 CI; 21 CIA). RESULTS. Dose-limiting toxicities were hyperbilirubinemia and hepatic transaminase elevations for CI-treated patients in addition to mucositis and diarrhea for CIA-treated patients. MTD for CI was clofarabine 22.5 mg/m2 intravenously daily × 5 and idarubicin 10 mg/m2 intravenously daily × 3. MTD for CIA was clofarabine 22.5 mg/m2 intravenously × 5, idarubicin 6 mg/m2 intravenously × 3, and cytarabine 0.75 g/m2 intravenously × 5 days. CONCLUSIONS. A phase 2 randomized trial is in process to compare activity between treatment arms. Cancer 2008. © 2008 American Cancer Society." @default.
• W2143342566 created "2016-06-24" @default.
• W2143342566 creator A5000750846 @default.
• W2143342566 creator A5028845635 @default.
• W2143342566 creator A5046097970 @default.
• W2143342566 creator A5055045706 @default.
• W2143342566 creator A5057822243 @default.
• W2143342566 creator A5077963154 @default.
• W2143342566 creator A5084290698 @default.
• W2143342566 creator A5085521139 @default.
• W2143342566 creator A5089428686 @default.
• W2143342566 creator A5090435894 @default.
• W2143342566 date "2008-10-15" @default.
• W2143342566 modified "2023-10-09" @default.
• W2143342566 title "Clofarabine combinations as acute myeloid leukemia salvage therapy" @default.
• W2143342566 cites W1976904568 @default.
• W2143342566 cites W1995697319 @default.
• W2143342566 cites W2040489908 @default.
• W2143342566 cites W2044041384 @default.
• W2143342566 cites W2069298406 @default.
• W2143342566 cites W2081708329 @default.
• W2143342566 cites W2081947065 @default.
• W2143342566 cites W2088819403 @default.
• W2143342566 cites W2102776788 @default.
• W2143342566 cites W2116171965 @default.
• W2143342566 cites W2131637500 @default.
• W2143342566 cites W2140291353 @default.
• W2143342566 cites W2145635831 @default.
• W2143342566 cites W2160881482 @default.
• W2143342566 cites W2244915568 @default.
• W2143342566 cites W2324265531 @default.
• W2143342566 cites W2589987812 @default.
• W2143342566 doi "https://doi.org/10.1002/cncr.23816" @default.
• W2143342566 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4163782" @default.
• W2143342566 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18756533" @default.
• W2143342566 hasPublicationYear "2008" @default.
• W2143342566 type Work @default.
• W2143342566 sameAs 2143342566 @default.
• W2143342566 citedByCount "50" @default.
• W2143342566 countsByYear W21433425662012 @default.
• W2143342566 countsByYear W21433425662013 @default.
• W2143342566 countsByYear W21433425662014 @default.
• W2143342566 countsByYear W21433425662015 @default.
• W2143342566 countsByYear W21433425662016 @default.
• W2143342566 countsByYear W21433425662017 @default.
• W2143342566 countsByYear W21433425662018 @default.
• W2143342566 countsByYear W21433425662019 @default.
• W2143342566 countsByYear W21433425662020 @default.
• W2143342566 countsByYear W21433425662022 @default.
• W2143342566 countsByYear W21433425662023 @default.
• W2143342566 crossrefType "journal-article" @default.
• W2143342566 hasAuthorship W2143342566A5000750846 @default.
• W2143342566 hasAuthorship W2143342566A5028845635 @default.
• W2143342566 hasAuthorship W2143342566A5046097970 @default.
• W2143342566 hasAuthorship W2143342566A5055045706 @default.
• W2143342566 hasAuthorship W2143342566A5057822243 @default.
• W2143342566 hasAuthorship W2143342566A5077963154 @default.
• W2143342566 hasAuthorship W2143342566A5084290698 @default.
• W2143342566 hasAuthorship W2143342566A5085521139 @default.
• W2143342566 hasAuthorship W2143342566A5089428686 @default.
• W2143342566 hasAuthorship W2143342566A5090435894 @default.
• W2143342566 hasBestOaLocation W21433425662 @default.
• W2143342566 hasConcept C126322002 @default.
• W2143342566 hasConcept C141071460 @default.
• W2143342566 hasConcept C2776694085 @default.
• W2143342566 hasConcept C2777198975 @default.
• W2143342566 hasConcept C2778041864 @default.
• W2143342566 hasConcept C2778397455 @default.
• W2143342566 hasConcept C2778496288 @default.
• W2143342566 hasConcept C2778729363 @default.
• W2143342566 hasConcept C2779117419 @default.
• W2143342566 hasConcept C71924100 @default.
• W2143342566 hasConcept C90924648 @default.
• W2143342566 hasConceptScore W2143342566C126322002 @default.
• W2143342566 hasConceptScore W2143342566C141071460 @default.
• W2143342566 hasConceptScore W2143342566C2776694085 @default.
• W2143342566 hasConceptScore W2143342566C2777198975 @default.
• W2143342566 hasConceptScore W2143342566C2778041864 @default.
• W2143342566 hasConceptScore W2143342566C2778397455 @default.
• W2143342566 hasConceptScore W2143342566C2778496288 @default.
• W2143342566 hasConceptScore W2143342566C2778729363 @default.
• W2143342566 hasConceptScore W2143342566C2779117419 @default.
• W2143342566 hasConceptScore W2143342566C71924100 @default.
• W2143342566 hasConceptScore W2143342566C90924648 @default.
• W2143342566 hasIssue "8" @default.
• W2143342566 hasLocation W21433425661 @default.
• W2143342566 hasLocation W21433425662 @default.
• W2143342566 hasLocation W21433425663 @default.
• W2143342566 hasLocation W21433425664 @default.
• W2143342566 hasOpenAccess W2143342566 @default.
• W2143342566 hasPrimaryLocation W21433425661 @default.
• W2143342566 hasRelatedWork W2018542229 @default.
• W2143342566 hasRelatedWork W2127583561 @default.
• W2143342566 hasRelatedWork W2143342566 @default.
• W2143342566 hasRelatedWork W2340871778 @default.
• W2143342566 hasRelatedWork W2467282880 @default.
• W2143342566 hasRelatedWork W2554844895 @default.
• W2143342566 hasRelatedWork W2559438007 @default.

• next